Similarly, pre-clinical evidence indicates inhibition of tumor growth by an AR degrader bavdegalutamide (ARV-110, a proteolysis targeting chimera, PROTAC) that especially in combination with abiraterone showed potent inhibition of growth in patient-derived xenograft and mouse model [66]. This evidence concerns the gene AR and neoplasm.